UK markets closed

NUVL Jun 2024 90.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
As of 12:08PM EDT. Market open.
Full screen
Previous close0.0500
Open0.0500
Bid0.0000
Ask5.0000
Strike90.00
Expiry date2024-06-21
Day's range0.0500 - 0.0500
Contract rangeN/A
Volume1
Open interest505
  • PR Newswire

    Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference

    Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 4:30 p.m. ET in NYC.

  • PR Newswire

    Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

    Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to NVL-655 for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have been previously treated with two or more ALK tyrosine kinase inhibitors (TKIs).

  • PR Newswire

    Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results

    Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline progress, reiterated key anticipated milestones, and reported first quarter 2024 financial results.